90.7 WMFE and 89.5 WMFV are Central Florida's primary provider of NPR programming and Classical Music. Part of the community since 1965, providing quality national and local news and programming. We inspire and empower all Central Floridians to discover, grow and engage within and beyond their world.
Support for 90.7 WMFE is provided by

Pfizer asks FDA to greenlight new omicron booster shots, which could arrive this fall

The new booster shot would be an update to Pfizer's current version of the shot, which was designed for the original strain of the coronavirus.
Image credit: Nam Y. Huh

The U.S. is one step closer to having new COVID-19 booster shots available as soon as this fall.

On Monday, the drugmakers Pfizer and BioNTech announced that they’ve asked the Food and Drug Administration to authorize an updated version of their COVID-19 vaccine — this one designed specifically to target the omicron subvariants that are dominant in the U.S.

More than 90% of cases are caused by the BA.4 and BA.5 subvariants, which took off this summer, but the vaccines being used were designed for the original coronavirus strain from several years ago.

Pfizer and BioNTech said they have submitted pre-clinical data on vaccine efficacy to the FDA, but did not share the data publicly.

The new “bivalent” booster — meaning it’s a mix of two versions of the vaccine — will target both the original coronavirus strain and the BA.4 and BA.5 omicron subvariants.

If the vaccine is authorized by the FDA, distribution could start “immediately” to help the country prepare for potential fall and winter surges of the coronavirus, Pfizer CEO Albert Bourla said in a statement.

Following the FDA’s guidance, the data the drugmakers are submitting represents a departure from what’s been used in earlier vaccine authorizations.

Instead of waiting for results from human trials, the FDA asked the drug companies to initially submit only the results of tests on mice, as NPR reported last week. Regulators will rely on those results — along with the human neutralizing antibody data from earlier BA.1 bivalent booster studies — to decide whether to authorize the boosters.

“We’re going to use all of these data that we’ve learned through not only this vaccine but decades of viral immunology to say: ‘The way to be nimble is that we’re going to do those animal studies,” Deepta Bhattacharya, an immunobiologist at the University of Arizona College of Medicine in Tucson, told NPR recently. “We’re really not going out too far on a limb here.”

Pfizer and BioNTech also report that they expect to start a human study on the safety and immunogenicity of the BA4/BA5 bivalent vaccine this month.

Earlier this year, vaccine makers presented U.S. and European regulatory authorities with an option for a bivalent vaccine that targeted an earlier version of the omicron variant, BA.1. While the plan was accepted in the U.K., U.S. regulators instead asked the companies to update the vaccines to target the newer subvariants.

Scientists say the development of COVID-19 vaccines may go the way of flu vaccines, which are changed every year to try to match the strains that are likely to be circulating.

Copyright 2022 NPR. To see more, visit https://www.npr.org.

Get The 90.7 WMFE Newsletter

Your trusted news source for the latest Central Florida news, updates on special programs and more.

Stay tuned in to our local news coverage: Listen to 90.7 WMFE on your FM or HD radio, the WMFE mobile app or your smart speaker — say “Alexa, play NPR” and you’ll be connected.

WMFE Journalistic Ethics Code | Public Media Code of Integrity